175 related articles for article (PubMed ID: 7487929)
1. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
[TBL] [Abstract][Full Text] [Related]
2. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
[TBL] [Abstract][Full Text] [Related]
3. Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin.
Wojcik EG; Simioni P; d Berg M; Girolami A; Bertina RM
Thromb Haemost; 1996 Jan; 75(1):70-5. PubMed ID: 8713782
[TBL] [Abstract][Full Text] [Related]
4. Derivatives of blood coagulation factor IX contain a high affinity Ca2+-binding site that lacks gamma-carboxyglutamic acid.
Morita T; Isaacs BS; Esmon CT; Johnson AE
J Biol Chem; 1984 May; 259(9):5698-704. PubMed ID: 6425296
[TBL] [Abstract][Full Text] [Related]
5. Membrane binding properties of the factor IX gamma-carboxyglutamic acid-rich domain prepared by chemical synthesis.
Jacobs M; Freedman SJ; Furie BC; Furie B
J Biol Chem; 1994 Oct; 269(41):25494-501. PubMed ID: 7929250
[TBL] [Abstract][Full Text] [Related]
6. The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX.
Liebman HA
Eur J Biochem; 1993 Mar; 212(2):339-45. PubMed ID: 7680311
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
Huang M; Furie BC; Furie B
J Biol Chem; 2004 Apr; 279(14):14338-46. PubMed ID: 14722079
[TBL] [Abstract][Full Text] [Related]
8. Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies.
Wojcik EG; Cheung WF; van den Berg M; van der Linden IK; Stafford DW; Bertina RM
Biochim Biophys Acta; 1998 Jan; 1382(1):91-101. PubMed ID: 9507074
[TBL] [Abstract][Full Text] [Related]
9. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
10. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.
Gillis S; Furie BC; Furie B; Patel H; Huberty MC; Switzer M; Foster WB; Scoble HA; Bond MD
Protein Sci; 1997 Jan; 6(1):185-96. PubMed ID: 9007991
[TBL] [Abstract][Full Text] [Related]
11. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
Liebman HA; Furie BC; Furie B
J Biol Chem; 1987 Jun; 262(16):7605-12. PubMed ID: 3108254
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for Ca2+ binding to the gamma-carboxyglutamic acid and epidermal growth factor-like regions of factor IX. Studies using intact domains isolated from controlled proteolytic digests of bovine factor IX.
Astermark J; Björk I; Ohlin AK; Stenflo J
J Biol Chem; 1991 Feb; 266(4):2430-7. PubMed ID: 1989994
[TBL] [Abstract][Full Text] [Related]
13. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
[TBL] [Abstract][Full Text] [Related]
14. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.
Cheung WF; Stafford DW; Sugo T
Thromb Res; 1996 Jan; 81(1):65-73. PubMed ID: 8747521
[TBL] [Abstract][Full Text] [Related]
15. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.
Freedman SJ; Furie BC; Furie B; Baleja JD
Biochemistry; 1995 Sep; 34(38):12126-37. PubMed ID: 7547952
[TBL] [Abstract][Full Text] [Related]
16. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
[TBL] [Abstract][Full Text] [Related]
17. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX.
Cheung WF; Wolberg AS; Stafford DW; Smith KJ
Thromb Res; 1995 Dec; 80(5):419-27. PubMed ID: 8588203
[TBL] [Abstract][Full Text] [Related]
18. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase.
Stanley TB; Wu SM; Houben RJ; Mutucumarana VP; Stafford DW
Biochemistry; 1998 Sep; 37(38):13262-8. PubMed ID: 9748333
[TBL] [Abstract][Full Text] [Related]
19. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
[TBL] [Abstract][Full Text] [Related]
20. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
Bertina RM; Van Der Linden IK
J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
